Lupin Ltd. shares surged nearly 3 percent in early trade on October 9 after the company announced plans to build a new state-of-the-art manufacturing facility in Coral Springs, Florida. At 09:16 am, Lupin was quoting at ₹1,959.20, up ₹53.50, or 2.81 percent, on the BSE.
Share price up 2.81% at ₹1,959.20
Market capitalisation stands at ₹89,488 crore
Stock trading 18.48% below 52-week high
$250 Million Investment to Boost Production Capacity
The new facility represents a cumulative investment of USD 250 million over five years, covering research & development, infrastructure, and capital expenditures. The site will be able to produce over 25 critical respiratory medicines, including lifesaving albuterol inhalers for children with asthma and service members both domestically and overseas.
Total investment of USD 250 million over five years
Facility to produce more than 25 respiratory medicines
Includes life-saving albuterol inhalers
Also Read : M&M Confirms No Plans to Demerge Auto and Tractor Businesses
Strategic Significance and Growth Plans
Christoph Funke, Chief Technical Operations Officer at Lupin, emphasized that the Coral Springs expansion is central to the company’s growth strategy. He added that the facility will complement Lupin’s existing presence in Florida, which houses its headquarters and Advanced Inhalation Research Center. The investment highlights Lupin’s commitment to innovation, quality, and reliable supply chains.
Expansion builds on existing Florida operations
Supports Lupin’s mission to ensure affordable medicines
Strengthens supply chain and US medicine security
Facility Details and Land Acquisition
The company has acquired more than 5 acres of land for the 70,000 square feet facility. This expansion underscores Lupin’s long-term commitment to growing its US manufacturing footprint and meeting increasing global demand for respiratory and critical care medications.
Facility spans 70,000 sq. ft on 5+ acres of land
Focus on long-term US market expansion
Supports production capacity for critical care medicines
Recent Operational Updates
Earlier this month, Lupin received four observations at its Pithampur unit from the USFDA. The company also launched two new products in the United States: Liraglutide Injection, 18 mg/3 mL prefilled pen, and Rivaroxaban Oral Suspension, 1 mg/mL.
USFDA inspection notes received for Pithampur unit
New launches: Liraglutide Injection and Rivaroxaban Oral Suspension
Strengthens Lupin’s US product portfolio
Stock Performance Overview
In the previous trading session, Lupin shares closed down 0.98 percent at ₹1,905.70. The stock touched a 52-week high of ₹2,403.45 on January 2, 2025, and a 52-week low of ₹1,774.00 on April 7, 2025. Currently, it is trading 18.48 percent below its 52-week high and 10.44 percent above its 52-week low, reflecting moderate volatility.
52-week high: ₹2,403.45; 52-week low: ₹1,774.00
Stock down 0.98% in previous session
Currently 10.44% above 52-week low
Useful Links
